Goldman Sachs has officially initiated coverage of Natera, a genetic testing company, assigning it a Neutral rating. The financial institution has set a price target of $245 for the stock, indicating its assessment of the company's current market position and potential for growth. This rating and target reflect Goldman Sachs' analysis of Natera's business fundamentals and market dynamics.
Related Articles
Don't miss out on breaking stories and in-depth articles.